Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines

Advances in Experimental Medicine and Biology

Volumn 431, Issue , 1998, Pages 591-594

  Bergman, Andries M ^a   Pinedo, Herbert M ^a   Veerman, Gijsbert ^a   Kuiper, Catharina M ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; ETOPOSIDE; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE;

CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0031834486     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5381-6_114     Document Type: Conference Paper

References (17)

1. R.P Abratt, W. Rezwoda, G. Falkson, L. Goedhals, D. Hacking, Efficacy and safety profile of gemcitabine in non-small cell lung cancer. Phase II study, J. Clin. Oncol., 12: 1535-1540 (1994).
2. B. Lund, O.P. Hansen, K. Theilade, M. Hansen, J.P. Neijt, Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients, J. Natl. Cancer Inst., 86: 1530-1533 (1994).
3. C.J.A. van Moorsel, G. Veerman, A.M. Bergman, A. Guechev, J.B. Vermorken, P.E. Postumus, G.J. Peters, Combination chemotherapy studies with gemcitabine, Sem. Oncol., in press.
4. V.W.T. Ruiz van Haperen, G. Veerman, J.B. Vermorken, G.J. Peters, 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines, Biochem. Pharmacol., 46: 762-766 (1993).
5. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, W. Plunkett, Action of 2′,2′-difluorodeoxycytidine on DNA synthesis, Cancer Res., 51: 6110-6117 (1991).
6. S. Eriksson, B. Kierszuk, B. Munch-Petersen, B. Oberg, N.G. Johansson, Comparison off the substrate specifities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs, Biochem. Biophys. Res. Comm., 176: 586-592 (1991).
7. V. Heinemann, Y-Z Xu, S. Chubb, A. Sen, L.W. Hertel, G.B. Grindey, W. Plukett, Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine, Mol. Pharmacol., 38: 567-572 (1990).
8. V.W.T. Ruiz van Haperen, G.J. Peters, New targets for pyrimidine antimetabolites for the treatment of solid tumours. II: Deoxycytidine kinase, Pharmacy World Sci., 16: 104-112 (1994).
9. J.A. Endicott and V. Ling, The biochemistry of P-glycoprotein-mediated multidrug resistance, Annu. Rev. Biochem., 58: 137-171 (1989).
10. C.E. Grant, G. Valdimarsson, D.R. Hipfner, K.C. Almquist, S.P.C. Cole, R.G. Deeley, Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs, Cancer Res., 54: 357-361 (1994).
11. B. Van Triest, H.M. Pinedo, F. Telleman, C.L. Van der Wilt, G. Jansen, G.J. Peters, Cross-resistancce to anti-folates in multi drug resisttant cell lines with P-glycoprotein or multi drug resistance related protein expression, Biochem. Pharm., in press.
12. Y.P. Keepers, P.E. Pizao, G.J. Peters, J. van Ark-Otte, B. Winograd, H.M. Pinedo, Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing, Eur. J. Cancer, 27: 897-900 (1991).
13. V.W.T. Ruiz van Haperen, G. Veerman, B.J.M. Braakhuis, J.B. Vermorken, E. Boven, A. Leyva, G.J. Peters, Deoxycytidine kinase and deoxycytidine deaminase activities in human xenografts, Eur. J. Cancer, 29A: 2132-2137 (1993).
14. V.W.T. Ruiz van Haperen, G. Veerman, E. Boven, P. Noordhuis, J.B. Vermorken, G.J. Peters, Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours, Biochem. Pharmacol, 48: 1327-1339 (1994).
15. C.H. Langeveld, C.A.M. Jongenelen, J.W.M. Theeuwes, J.P.A. Baak, J.J. Heimans, J.C. Stoof, G.J. Peters, The antiproliferative effect of 8-chloro-adenosine, an metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics, Biochem. Pharm., 53:1441-148 (1997).
16. A.M. Bergman, V.W.T Ruiz van Haperen, G. Veerman, C.M. Kuiper, G.J. Peters, Synergistic interaction between cisplatin and gemcitabine in vitro, Clin. Cancer Res., 2: 521-530 (1996).
17. P.B. Jensen, B. Holm, M. Sorensen, I.J. Christensen, M. Sehested, In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine, Brit. J. Cancer, 75: 869-877 (1997).